Association of digestive symptoms with severity and mortality of COVID-19: A protocol for systematic review and meta-analysis.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
23 Oct 2020
23 Oct 2020
Historique:
entrez:
30
10
2020
pubmed:
31
10
2020
medline:
11
11
2020
Statut:
ppublish
Résumé
Gastrointestinal manifestations are common in patients with COVID-19, but the association between specific digestive symptoms and COVID-19 prognosis remains unclear. This study aims to assess whether digestive symptoms are associated with COVID-19 severity and mortality. We will search PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials up to September, 2020, to identify studies that compared the prevalence of at least one specific digestive symptom between severe and non-severe COVID-19 patients or between non-survivors and survivors. Two independent reviewers will assess the risk of bias of the included cohort studies using the modified Newcastle-Ottawa Scale. Meta-analyses will be conducted to estimate the pooled prevalence of individual symptoms using the inverse variance method with the random-effects model. We will conduct subgroup analyses, sensitivity analyses, and meta-regression analyses to explore the sources of heterogeneity. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach will be used to assess the quality of the evidence. The results of this study will be published in a peer-reviewed journal. Our meta-analysis will comprehensively evaluate the association between different digestive symptoms and the severity and mortality of patients infected with COVID-19. This study will provide evidence to help determine whether special protective measures and treatment options are needed for patients with digestive system comorbidities during the COVID-19 pandemic. INPLASY202090055.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal manifestations are common in patients with COVID-19, but the association between specific digestive symptoms and COVID-19 prognosis remains unclear. This study aims to assess whether digestive symptoms are associated with COVID-19 severity and mortality.
METHODS
METHODS
We will search PubMed, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials up to September, 2020, to identify studies that compared the prevalence of at least one specific digestive symptom between severe and non-severe COVID-19 patients or between non-survivors and survivors. Two independent reviewers will assess the risk of bias of the included cohort studies using the modified Newcastle-Ottawa Scale. Meta-analyses will be conducted to estimate the pooled prevalence of individual symptoms using the inverse variance method with the random-effects model. We will conduct subgroup analyses, sensitivity analyses, and meta-regression analyses to explore the sources of heterogeneity. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach will be used to assess the quality of the evidence.
RESULTS
RESULTS
The results of this study will be published in a peer-reviewed journal.
CONCLUSION
CONCLUSIONS
Our meta-analysis will comprehensively evaluate the association between different digestive symptoms and the severity and mortality of patients infected with COVID-19. This study will provide evidence to help determine whether special protective measures and treatment options are needed for patients with digestive system comorbidities during the COVID-19 pandemic.
INPLASY REGISTRATION NUMBER
UNASSIGNED
INPLASY202090055.
Identifiants
pubmed: 33120773
doi: 10.1097/MD.0000000000022736
pii: 00005792-202010230-00049
pmc: PMC7581056
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e22736Références
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Med Virol. 2020 Jul;92(7):807-813
pubmed: 32222986
EClinicalMedicine. 2020 Apr 05;21:100331
pubmed: 32292899
Clin Infect Dis. 2020 Nov 19;71(16):2089-2098
pubmed: 32361738
Lancet Gastroenterol Hepatol. 2020 Jul;5(7):667-678
pubmed: 32405603
J Clin Epidemiol. 2016 Jun;74:73-9
pubmed: 26780259
Am J Gastroenterol. 2020 May;115(5):766-773
pubmed: 32287140
Lancet. 2020 Mar 14;395(10227):848-850
pubmed: 32151326
Int J Infect Dis. 2020 Jun;95:332-339
pubmed: 32334118
Am J Transplant. 2020 Jul;20(7):1800-1808
pubmed: 32330343
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
PLoS One. 2020 May 11;15(5):e0233147
pubmed: 32392262
J Infect. 2020 Jul;81(1):e89-e92
pubmed: 32305487
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
J Infect. 2020 Aug;81(2):e93-e95
pubmed: 32417309
J Clin Epidemiol. 2016 Nov;79:150-158.e1
pubmed: 27421684
Hepatol Res. 2020 Aug;50(8):924-935
pubmed: 32386449
Gastroenterology. 2020 Jul;159(1):81-95
pubmed: 32251668
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3404-3410
pubmed: 32271459
Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):653-661
pubmed: 32418852
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Health Policy. 2015 Apr;119(4):503-10
pubmed: 25260911
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Gut. 2020 Jun;69(6):1143-1144
pubmed: 32139552
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Liver Int. 2020 Jun;40(6):1321-1326
pubmed: 32239591